Creative Biolabs supports fibronectin-domain discovery through our Alternative Scaffolds expertise and this dedicated 10Fn3 scaffold selection service for research programs seeking custom binders with compact architecture, flexible loop engineering, and practical screening workflows. Our platform is designed for phage display screening of 10Fn3/FN3-like libraries against recombinant proteins, peptides, membrane-associated targets, and selected cell-based systems, helping research teams identify fibronectin-based binders for research, engineer 10Fn3 domain proteins against selected targets, and support early candidate evaluation. Here, Adnectin-like refers to scaffold format and engineering logic related to the fibronectin type III domain rather than a claim that classical Adnectin industrial platforms are themselves based on phage display workflows.
Why 10Fn3 and Fibronectin Domain Screening Matters
The tenth fibronectin type III domain is a practical scaffold for binder discovery because it is compact, independently folded, and readily diversified through its exposed loop regions. As 10Fn3 does not depend on internal disulfide bonds for folding, it fits well with phage display workflows, soluble expression, and a broad range of in vitro research assays. For teams seeking to discover fibronectin-based binders for research, this scaffold provides a balanced combination of structural simplicity, engineering flexibility, and sequence-level traceability.
Its value becomes even more evident when standard reagents lack sufficient selectivity or cannot be efficiently adapted to a defined target study. In receptor-binding research, ligand-blocking studies, and early target validation, investigators often need more than a basic screening output. They usually require a workflow that supports:
Rational library design
Controlled target-directed enrichment
Clone-level confirmation
Sequence-based candidate selection
At the same time, 10Fn3/FN3-like screening outcomes are strongly influenced by overall project design. Common challenges may include:
Weak or biased target presentation
Poor loop diversity balance
Enrichment of non-ideal clones
Background binding in cell-based screening
Limited follow-up characterization
For this reason, an effective 10Fn3 scaffold selection campaign should extend beyond simple panning alone. It should bring together target assessment, selection strategy, clone review, and binder characterization within one coordinated process. To address these needs, our 10Fn3 scaffold selection service offers a more structured and decision-oriented route from library screening to research-stage candidate identification.
Our 10Fn3 Scaffold Selection Service
Creative Biolabs offers a dedicated service for phage display screening of 10Fn3/FN3-like libraries and related fibronectin domain variants. This workflow is intended for research teams pursuing target-focused discovery. Modules are selected based on project scope; not all campaigns include library construction, soluble reformatting, or biophysical affinity measurement by default. Depending on project requirements, we can support de novolibrary design, screening from an existing 10Fn3-format repertoire, loop-focused library design or rediversification, positive-clone recovery and review, monoclonal validation, and preliminary binding or affinity characterization in agreed assay formats.
Our service scope can be configured around one or more of the following modules:
Library Design
10Fn3 or FN3-like library design with project-defined loop diversification or rediversification strategy.
Biopanning
Screening against recombinant proteins, peptides, particles, or selected cell-associated targets when compatible with display-based enrichment.
Counter-Selection
Implementation of subtractive selection to reduce matrix, format-related, or off-target binding where appropriate.
Monoclonal ELISA
High-throughput monoclonal phage ELISA or equivalent primary binder screening for clone-level review.
Sequence ID
Sequence identification and alignment of validated positive clones to support uniqueness and motif review.
Binding Characterization
Soluble confirmation and preliminary binding or affinity characterization of selected candidates in agreed assay formats.
This flexible setup is particularly suitable for teams aiming to discover fibronectin-based binders for research, compare performance across target classes, or generate an initial binder panel before more extensive optimization. The output is a research-stage binder panel rather than a guaranteed functional blocker or developable lead candidate.
Service Workflow for Fibronectin Domain Phage Display
Phase I
Project Review and Library Strategy
We begin by reviewing the target category, known biology, preferred screening mode, and downstream research use case. For a new campaign, this stage may include discussion of loop randomization regions, theoretical diversity, framework preservation, and screening stringency. For a legacy campaign, we can also work with a client-supplied scaffold design or prebuilt library.
Phase Ⅱ
Target Preparation and Panning Design
Targets may be handled as purified recombinant proteins, tagged proteins, biotinylated materials, immobilized antigens, or selected cell-based systems. Feasibility depends on target integrity, presentation mode, abundance, and compatibility with display-based enrichment. Based on the target type, we define the number of rounds, washing pressure, elution strategy, and any optional subtraction steps. When appropriate, we incorporate negative selection to reduce background enrichment and improve specificity.
Phase Ⅲ
Multi-Round Enrichment
The phage library is exposed to the target through iterative panning. Selection conditions can be tuned across rounds to enrich candidates with improved binding profiles and may help bias recovery toward stronger or more selective binders depending on target presentation and assay design. Enrichment is monitored through output trends and binding readouts, allowing the campaign to progress from broad diversity capture toward narrower candidate recovery.
Phase Ⅳ
Monoclonal Screening and Sequence Analysis
Individual clones are screened for target reactivity and then sequenced to identify unique binders, redundancy patterns, and enriched motifs. This step is essential for distinguishing true positives from recurrent background clones and for defining a manageable panel for follow-up characterization.
Selected sequences can be reformatted for soluble production and evaluated in assay formats appropriate to the project. Depending on the target and study objective, this may include binding confirmation, comparative ranking, and preliminary affinity-related analysis for early-stage candidate triage. Assay depth is defined by project scope rather than assumed as a default full biophysical package.
Samples & Deliverables
Sample Requirements
Sample planning has a direct impact on screening quality. For most projects, clients may provide purified target proteins, tagged recombinant proteins, peptides, membrane preparations, stable cell lines, transiently expressing cells, or subtraction control materials. If you already have a preferred epitope format or assay context, we can align the panning design accordingly.
Typical information requested at project initiation includes target identity, species origin, recommended handling conditions, known binding partners, desired screening mode, and any anticipated cross-reactivity concerns. When a cell-based campaign is preferred, information on target expression status and control cells is also highly valuable.
Deliverables and Handover
Deliverables are defined by project scope, but commonly include a screening summary, panning record, positive clone list, sequence results, primary binding data, and a ranked set of candidate binders for further research use. If soluble confirmation is included, the package may also contain an expression summary and binding or affinity-related data generated in the agreed assay format.
Our handover process is intended to support decision-making rather than simply transfer large volumes of uninterpreted data. Instead of providing raw outputs alone, we organize findings around clone uniqueness, enrichment trends, binding performance, and next-step suitability. This makes it easier for your team to decide whether to proceed with re-screening, focused engineering, affinity improvement, or mechanism-oriented follow-up studies.
How to Start Your Custom Adnectin-Like Screening Project
If your team needs to engineer 10Fn3 domain proteins against selected targets, the most efficient starting point is often a brief technical discussion covering target class, available material, desired binder profile, and downstream assay plan. Some groups approach us with a validated antigen and a clearly defined screening route. Others begin only with the biological question they need to address. Both starting points are workable.
We can also help determine whether your project is better suited to recombinant-protein panning, cell-based selection, subtraction-enhanced screening, or a staged workflow that begins with broader discovery and proceeds to more selective characterization. Cell-based enrichment is recommended only when target expression level, background profile, and control-cell strategy are suitable for differential selection. For early feasibility projects, a compact campaign may generate initial binders and sequence diversity data. For more demanding research programs, we can establish a longer route that includes clone confirmation and project-defined binding characterization.
Projects that are usually a good fit include target-focused binder discovery, comparative scaffold evaluation, and early screening programs that need a research-stage binder panel. Projects aimed directly at obtaining a guaranteed functional blocker, a developable therapeutic lead, or a full downstream translational package generally require additional stages beyond this screening-focused service.
Discuss Your Project
Published Data Supporting 10Fn3 and FN3-Like Screening
Published studies continue to support the fibronectin type III domain as a well-established scaffold for display-based binder discovery. In the review by Chandler and Buckle, Figure 1 presents a concise structural overview of fibronectin type III domain-based scaffolds and highlights both canonical loop-engineering regions and the broader structural plasticity of FN3-derived scaffolds. In addition to the BC, DE, and FG loops, the figure helps illustrate that engineerable features are not limited to the north-loop region alone. This broader structural view is useful for understanding scaffold design flexibility, diversification logic, and candidate interpretation in 10Fn3/FN3-like screening.
At the same time, this publication should be read as scaffold-level support rather than as a direct validation of one fixed commercial workflow. It supports the fibronectin type III domain as an engineerable scaffold and summarizes how related formats have been used across display and evolution strategies. In this service page, Adnectin-like refers to similarity in scaffold framework and engineering logic, rather than a claim that the classical Adnectin industrial platform itself is defined by phage display. For research teams planning fibronectin domain phage display, this evidence is therefore most useful for supporting library design rationale, selection strategy discussion, and interpretation of research-stage binder outputs.
More broadly, the same review also supports three practical takeaways relevant to service planning: the fibronectin type III domain is structurally engineerable, compatible with multiple display or evolution formats, and associated with a broad downstream application space. Together, these points strengthen the scientific rationale for offering a screening-focused 10Fn3/FN3-like discovery service while keeping the service boundary clearly at the research and early evaluation stage.
Fig.1 Structural features of fibronectin type III domain-based scaffolds relevant to 10Fn3 and FN3-like screening.1
FAQs
Q: What targets can be used for 10Fn3 scaffold selection?
A: We can design campaigns around recombinant proteins, peptides, protein complexes, particles, and selected cell-based targets, depending on project objectives, sample quality, and compatibility with display-based enrichment.
Q: Can you work with a client-provided 10Fn3 library?
A: Yes. We can evaluate the existing library format, display compatibility, and screening feasibility, and then build the panning and characterization plan around that resource.
Q: Do you support cell-based Adnectin-like screening?
A: Yes. Cell panning can be considered when epitope presentation or membrane context is important. In such cases, target expression level, background profile, subtraction design, and appropriate control cells are particularly important.
Q: What data are typically included in the final package?
A: Depending on scope, deliverables may include a panning summary, monoclonal screening results, sequence information, candidate ranking, and project-defined binding or affinity-related characterization data.
Reference:
Chandler, Peter G., and Ashley M. Buckle. "Development and Differentiation in Monobodies Based on the Fibronectin Type 3 Domain." Cells 9.3 (2020): 610. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cells9030610
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
Fig.1 Structural features of fibronectin type III domain-based scaffolds relevant to 10Fn3 and FN3-like screening.1
